Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration
Croma-Pharma (Croma) today announced the addition of juvenus to its product portfolio. It is an injectable, elastic, colourless and reabsorbable gel, based on polymerized polynucleotides (PDRN)1,2 of natural origin, which hydrates the skin and restores tissue elasticity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005466/en/
Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration (Photo: Business Wire)
juvenus is produced by a European certified manufacturer and distributed by Croma. In a first phase Croma will market the product within its network of affiliated sales companies (AT, FR, DE, NL, PL, PT, RO, ES, CH, UK, IT), followed by other European markets via independent distribution partners.3
Innovative mode of action to fight signs of skin aging
Thanks to its biochemical properties, juvenus improves skin elasticity and is effective against various signs of aging, such as wrinkles, loss of skin firmness or skin tone. The elastic and injectable gel is based on polymerized polynucleotides (PDRN), showing several positive effects on the skin:
- Antioxidative effect: The enzyme-related degradation of polynucleotide molecules can lead to an amplification of protective activities against free radicals. 4
- Moisturization: The hydrophilic and polyanionic structure enables PDRN to bind water molecules, resulting in an intensive moisturization of the tissue.
- Creation of an optimal environment for fibroblast growth: Extensive moisturization and the antioxidative activity contribute to the creation of an optimal physiological environment for the growth of the fibroblasts favoring the restoration of the tissue elasticity.5
Two concentrations for different types of skin blemishes
juvenus is available in two concentrations and suitable for all skin types and age groups:
- juvenus 2%, medium: slightly deeper wrinkles, such as superficial perioral wrinkles, cheek wrinkles, medium scars
- juvenus 2,5%, strong: medium-deep wrinkles and larger areas of the body, such as neck, back of the hands, abdomen, cleavage, thighs and glutes, nasogenien wrinkles, deep/large scars
Broad range of indications for facial and body treatments with a proven safety profile
The application range of juvenus is extensive and stretches from the treatment of slightly deeper facial wrinkles to the treatment of larger areas of the body.
juvenus shows a proven safety profile due to the PDRN extraction and purification at high temperature – a procedure that allows to recover an over 95% pure active substance with inactivated proteins and peptides. The latter guarantees the safety of the product and the lack of immunological side effects.
"Croma always strives to bring exceptional products to the market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable with an innovative mode of action that targets the signs of skin aging," comments Managing Director Andreas Prinz.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.
1 Müller Esterl, Biochemie. 1. Auflage 2004, Elsevier
2 Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224
3 available with CE 0373
4 Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.
5 Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201– 209.
PRJ0821
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005466/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Enters Collaboration Agreement with Business Meets Culture18.11.2025 16:30:00 EET | Press release
Andersen Consulting expands its global reach through a Collaboration Agreement with Business Meets Culture (BMC), a global strategy consultancy with locations in Latin American, Europe, and the U.S. Anchored in cultural intelligence and human insight, BMC specializes in strategy, brand strategy, commercial planning, innovation, and transformation; always. Through proprietary approaches and cross-disciplinary teams, BMC helps companies connect strategy to people by translating trends, behaviors, and business tensions into meaningful opportunities for business growth. The firm works with leading companies in various industries including consumer goods, financial services, telecommunications, technology. “Collaborating with Andersen Consulting allows us to amplify the reach and impact of our culturally grounded strategic work,” said Fernando Parodi, CEO of BMC. “Together, we’re positioned to offer organizations sharper perspective, greater foresight, and actionable strategies that drive s
Aspect Expands Cloud Workforce Experience and Developer Tools to New Regions and Introduces AI-Powered Forecasting18.11.2025 16:00:00 EET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, today announced its Q4 2025 product release, delivering AI-powered predictive forecasting for call volume, regional expansion into Canada, UK, and Europe, and new employee performance capabilities. The release represents a significant step forward in Aspect's mission to empower workforces with intelligent, modern tools that drive operational efficiency and employee engagement. AI-Driven Forecasting Brings New Precision and Agility to Workforce Planning The enhanced Forecast Dashboard introduces Predictive Forecasting with built-in AI intelligence. This new feature automatically generates four-week call volume forecasts that refresh daily, eliminating manual setup and enabling planners to make faster, more confident scheduling decisions. By analyzing historical data with advanced algorithms, it delivers more accurate, assumption-free predictions that adapt to changing demand patterns. "Forecasting is one of the mo
Gurobi Releases Version 13.0 with Improved Performance and New Solving Capabilities18.11.2025 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the release of Gurobi 13.0. This latest version represents a significant advancement in Gurobi’s mission to help organizations tackle increasingly complex optimization challenges with greater speed and flexibility. Version 13.0 introduces performance improvements across core model types, new algorithm support for large-scale and nonlinear problems, GPU acceleration, and expanded cloud-native functionality. “Today’s organizations face optimization challenges that are often domain-specific and more complex than ever,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “With Gurobi 13.0, we’re extending our technology to handle even larger models and more nonlinear problem types—delivering measurable speed-ups and greater flexibility across a wide range of applications.” Enhancements in the Gurobi Optimizer 13.0 include: A faster core solver, particularly for difficult mixed-integer programmin
FireMon Expands Zero Trust Microsegmentation Coverage with Illumio, VMware NSX, and Zscaler18.11.2025 16:00:00 EET | Press release
FireMon, the leading network security and firewall policy management company, today detailed expanded support for Zero Trust microsegmentation across hybrid environments, including a deeper integration with Illumio and continued coverage for VMware NSX and Zscaler. By normalizing, analyzing, and continuously validating segmentation intent across network, virtual, and host enforcement points, FireMon helps security teams operationalize Zero Trust at enterprise scale. “The future isn’t more consoles,” said Jody Brazil, CEO of FireMon. “It’s one policy playbook that proves control efficacy every day and the evidence to back it up.” Organizations using FireMon to unify segmentation and firewall governance report measurable outcomes, including up to a 90% reduction in compliance reporting time through consolidated policy data and faster validation and change reviews across the hybrid networks. They also eliminate blind spots between virtual, host, and network enforcement points, strengtheni
Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy18.11.2025 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Silicon Labs has selected Rimini Street as its strategic partner to maximize the value of its SAP ECC 6.0 investment. This collaboration provides the U.S.-based semiconductor manufacturer with long-term SAP maintenance and professional services to accelerate modernization without costly upgrades or business disruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118277544/en/ Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy Partnership Reduces Technical Debt and Accelerates Modernization Silicon Labs first engaged Rimini Street’s professional services team, Rimini Consult™, to develop a strategic ERP roadmap leading to a multi-system project
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom